ABOS
Acumen Pharmaceuticals Inc

1,114
Mkt Cap
$118.12M
Volume
17,440.00
52W High
$2.46
52W Low
$0.8551
PE Ratio
-0.88
ABOS Fundamentals
Price
$1.93
Prev Close
$1.95
Open
$1.96
50D MA
$1.86
Beta
1.44
Avg. Volume
423,621.61
EPS (Annual)
-$1.71
P/B
1.27
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat reports. One...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $8.00 by Analysts at Bank of America
Bank of America cut their price objective on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday...
MarketBeat·9d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Acumen Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·12d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·15d ago
News Placeholder
Preview: Acumen Pharmaceuticals's Earnings
read more...
Benzinga·17d ago
News Placeholder
Acumen Pharmaceuticals Earnings Preview
read more...
Benzinga·1y ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q2 2024 Earnings of ($0.26) Per Share
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acumen Pharmaceuticals in a note issued to...
Zolmax·2y ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) vs. Inhibrx (NASDAQ:INBX) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) and Inhibrx (NASDAQ:INBX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two...
Zolmax·2y ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,020,000 shares, an...
Zolmax·2y ago
News Placeholder
HC Wainwright Weighs in on Acumen Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ABOS)
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS Free Report) Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals...
Zolmax·2y ago

Latest ABOS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.